Among the seven published cases, only two out of seven cases (29%) reported no progression of tumor growth: one corticotroph carcinoma treated with EVE (7.5 mg) + Capecitabine followed by EVE (7.5–10 mg) + RT showed no increase in tumor volume for 5 months (58), and an aggressive PRL secreting tumor treated with EVE 10mg + octreotide showed stable tumor volume for 12 months (25). The gene discussed is PRL; the disease is neoplasm.